Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.

Also called NCT03531905

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 242 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03531905
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03531905. Randomized; triple masking; primary purpose treatment. Start 2018-05-09 (actual); primary completion 2019-06-18 (actual). Results posted on 2020-04-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Condition
Cholesterolemia
Intervention (Drug)
Bempedoic acid + Ezetimibe FDC Oral Tablet
Intervention (Drug)
Ezetimibe 10 mg Oral Tablet
Intervention (Drug)
Placebo Oral Tablet
Intervention (Drug)
Placebo oral capsule
Lead sponsor
Esperion Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03531905
Content hash
79aff5ece583e255b3386b206bdac849e188c90766c92d499c04bbf29c4b66d6